Boston, MA, United States of America

Denis Titov

USPTO Granted Patents = 1 

Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2024

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Denis Titov: Innovator in Mitochondrial Disease Treatment

Introduction

Denis Titov is a prominent inventor based in Boston, MA (US). He has made significant contributions to the field of mitochondrial diseases through his innovative research and inventions. His work focuses on developing solutions for conditions associated with mitochondrial dysfunction.

Latest Patents

Denis Titov holds a patent for "Protein prostheses for mitochondrial diseases or conditions." This invention encompasses water-forming NADH and NADPH oxidases, which are utilized to treat various mammalian diseases or conditions linked to an elevated NADH/NAD+ ratio or NADPH/NADP+ ratio. The patent addresses pathologies such as disorders caused by defects in the mitochondrial respiratory chain, glucose metabolism disorders, cancers associated with reductive stress, and aging. Additionally, this invention serves as a research tool for investigating the effects of exogenous water-forming NADH or NADPH oxidases on mammalian cell metabolism, including human cells.

Career Highlights

Denis Titov is affiliated with The General Hospital Corporation, where he continues to advance his research in mitochondrial diseases. His work has garnered attention for its potential to improve treatment options for patients suffering from these complex conditions.

Collaborations

Denis collaborates with esteemed colleagues, including Vamsi K Mootha and Valentin Cracan. Their combined expertise enhances the research efforts aimed at understanding and treating mitochondrial disorders.

Conclusion

Denis Titov's innovative contributions to the field of mitochondrial disease treatment highlight the importance of research and invention in addressing complex health challenges. His patent and ongoing work promise to pave the way for new therapeutic approaches in the future.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…